CVRx Stock

CVRx EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of CVRx (CVRX) as of Aug 15, 2026 is -2.73. In the previous year, EV/EBIT (Enterprise Value to EBIT) was -2.34 — a change of 16.88% (lower).

EV/EBIT

-2.73

YoY

16.88%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of CVRx is 2026 -2.73 . EV/EBIT (Enterprise Value to EBIT) of CVRx was 2025 -2.34 . It decreases by 16.88% lower compared to the previous year.

The CVRx EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
0.00 base
Jan 1, 2020
0.00 base
Jan 1, 2021
-0.50 base
Jan 1, 2022
-0.72 base
Jan 1, 2023
-1.24 base
Jan 1, 2024
-0.68 base
Jan 1, 2025
-1.58 base
Jan 1, 2026 (e)
-1.22 base
YEARPRICE-TO-EBIT
2026 est -1.22
2025 -1.58
2024 -0.68
2023 -1.24
2022 -0.72
2021 -0.50
2020 -
2019 -
Access this data via the Eulerpool API

CVRx Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides CVRx's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates CVRx's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots CVRx's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if CVRx grows earnings faster than its peers.

CVRx Stock analysis

What does CVRx do? CVRx Inc is a medical technology company that is revolutionizing the global market for treatment-resistant hypertension patients with its innovative "Baroreflex Activation Therapy" (BAT) system. The company was founded in 2001 and has its headquarters, development, manufacturing, and distribution facility in Minneapolis, Minnesota. With its innovative products and medical expertise, the company aims to become a global leader in medical research and development of apps and medical devices. The company was founded by Dr. Robert Kieval and his partner in medical research, Dr. Casey Cunningham. Together, they identified a potential treatment gap for patients who were unresponsive to existing methods or unable to receive appropriate therapy due to comorbidities. They decided to develop a novel technology that activates the body's natural regulatory system, the baroreflex system. With a clinical expert team in Minneapolis, they developed an implantable device connected to specific pressure zones in the neck through an electrode. The device artificially stimulates the baroreflex and regulates the blood pressure system. After many years of clinical tests and studies, the company received FDA approval in 2019. The company is now publicly listed, and its products are available worldwide. CVRx's business model is based on the research, development, production, and marketing of innovative medical devices and technologies. The focus is on improving patients' quality of life and advancing medical research. The products and therapies are distributed globally through contractual partners and subsidiaries. In addition to developing and marketing medical devices, the company conducts research to develop innovative diagnostic and therapeutic methods. The needs of patients and medical research are always the central focus. CVRx Inc specializes in the development and manufacture of implantable electronic devices for the treatment of patients with chronic cardiovascular diseases. The company's main product is the BAROSTIM NEO System, which is CE-certified in Europe. The system consists of two components: an implanted device and an external remote control. The device is surgically placed below the collarbone, and an electrode is inserted into a carotid artery. The remote control is used to regulate the electrical impulses delivered by the device to the carotid artery, activating the baroreflex system. Clinical studies have shown that BAT therapy is effective in lowering systolic blood pressure in patients with severe and persistent hypertension and can also have positive effects on heart failure patients. The company plans to use the BAROSTIM NEO System for other conditions, such as chronic kidney disease or sleep apnea. CVRx also invests in the development of mobile applications and software to support data analysis and patient monitoring. In summary, CVRx Inc is a medical technology company specialized in the development and manufacture of implantable electronic devices. The company is revolutionizing the global market for treatment-resistant hypertension patients with its Baroreflex Activation Therapy (BAT) system. The company focuses on improving patients' quality of life and advancing medical research. In addition to the BAROSTIM NEO System, the company conducts research to develop innovative diagnostic and therapeutic methods. CVRx is one of the most popular companies on Eulerpool.

Frequently Asked Questions about CVRx stock

EV/EBIT (Enterprise Value to EBIT) of CVRx is -2.73 in 2026.

EV/EBIT (Enterprise Value to EBIT) of CVRx changed from -2.34 to -2.73, representing a 16.88% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of EV/EBIT (Enterprise Value to EBIT) CVRx since 2006 – with annual values, charts, and detailed analysis.

The EV/EBIT ratio measures a company's enterprise value relative to its operating earnings. It accounts for debt, making it useful for comparing companies with different capital structures.

EV/EBIT = Enterprise Value / Earnings Before Interest and Taxes

To evaluate EV/EBIT (Enterprise Value to EBIT)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for EV/EBIT (Enterprise Value to EBIT).

A 'good' varies by industry and company stage. On Eulerpool, you can compare EV/EBIT (Enterprise Value to EBIT)'s CVRx with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Valuation — CVRx

All Key Metrics — CVRx